Impacts of Adaptive Coronavirus Evolution on Viral Membrane Fusion
冠状病毒适应性进化对病毒膜融合的影响
基本信息
- 批准号:10727448
- 负责人:
- 金额:$ 24.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-14 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAffinityAmino Acid SubstitutionAmino AcidsAnimalsAntibodiesApicalBindingBiochemicalBiologicalBiological AssayCell membraneCellsCollectionCommunicationCommunitiesComplexCoronavirusCoronavirus spike proteinDetectionDistantEndocytosisEngineeringEquilibriumEvaluationEvolutionFutureGlycoproteinsGoalsHumanInfectionKineticsLinkMeasuresMediatingMembrane FusionMiddle East Respiratory Syndrome CoronavirusMolecular ConformationMutationPathway interactionsPeptide HydrolasesPeptidesPredispositionPropertyProtein ConformationProtein DynamicsProteinsReceptor CellRecombinantsRepliconResistanceSARS-CoV-2 B.1.1.529SARS-CoV-2 spike proteinSARS-CoV-2 variantSiteStructureSurfaceSystemVariantViralViral Drug ResistanceVirulenceVirusVirus ReceptorsVirus SheddingVirus-like particleconformational conversiondriving forceglobal healthinhibitorinsightreceptorreceptor bindingrecombinant virusresistance mutationtooltransmission processvariants of concernviral fitnessvirus tropism
项目摘要
PROJECT SUMMARY
The continuous adaptation of SARS-CoV-2 generates variants of concern (VOC). New VOCs arise
independently and outcompete previous ones, consistent with ever increasing viral fitness. Most VOC
adaptations reside in the spikes (S), the complex multidomain glycoprotein trimers that bind viruses to cells
and mediate virus-cell membrane fusion. Well-characterized adaptations in the S receptor binding domains
(RBDs) alter RBD structural dynamics, receptor affinities, and antibody interactions. However, adaptations in
other S domains remain largely under-evaluated. This includes the S2 domains that execute virus-cell
membrane fusion. This proposal aims to elucidate consequences of VOC adaptive changes in the S2 domains.
The current VOC, omicron (o), has accumulated over six S2 mutations. Our central objective is to evaluate the
ways these and other S2 adaptations alter S protein dynamics to facilitate human cell entry. We will utilize a
collection of viral membrane fusion and cell entry assay systems to determine whether S2 changes reset the
dynamics of transient S protein intermediate states. These transitory states include RBD elevations that control
receptor binding and S2 refoldings from prefusion to fusion intermediate and through to postfusion
configurations. Our assay systems will employ fusion-competent virus-like particles (VLPs) for sensitive
evaluation of entry steps, soluble receptors as probes for RBD exposures, HR2 peptides for detection of
specific S transitional intermediates, replication-competent VSVSARS-CoV-2-S for selecting HR2 peptide-resistant
variants, and SARS-CoV-2 replicons and recombinant SARS-CoV-2 viruses for convincingly assigning specific
S2 amino acid substitutions to consequential redirection of virus-cell entry pathways.
Our preliminary results suggest that omicron S2 adaptations operate allosterically to alter S-receptor
interactions. The first aim will determine how S2 fusion domains control RBDs and their interactions
with receptors. We will identify specific VOC S2 mutations that control receptor reactivity and S stability. We
will determine how these mutations change viral entry requirements. Our initial results also suggest that
omicron S2 mutations change the pace of the conformational transitions facilitating membrane fusion. The
second aim will determine how S2 mutations control dynamics of fusion domains. We will determine
whether the rates of S2 structural transitions vary between VOCs. We will also select and characterize variants
resistant to inhibitors of the S2 structural dynamics and will find out whether these resistant variants have
unique requirements for the receptors and proteases that determine cell susceptibility to infection.
The results of this study will clarify currently obscure selective forces driving the human adaptation of past (α,
β, γ, δ), current (ο), and future VOCs. We expect the results will illuminate properties of the membrane fusion –
inducing S2 domains in ways that reveal new targets for inhibition of CoV entry.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas Miller Gallagher其他文献
Thomas Miller Gallagher的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas Miller Gallagher', 18)}}的其他基金
Dissecting the peptide motifs controlling coronavirus infections
剖析控制冠状病毒感染的肽基序
- 批准号:
10648391 - 财政年份:2023
- 资助金额:
$ 24.48万 - 项目类别:
Entry and pathogenesis of two human coronaviruses
两种人类冠状病毒的进入和发病机制
- 批准号:
8055141 - 财政年份:2011
- 资助金额:
$ 24.48万 - 项目类别:
UBIQUITIN AND CELLULAR FACTORS IN CORONAVIRUS ASSEMBLY
冠状病毒组装中的泛素和细胞因子
- 批准号:
7646778 - 财政年份:2009
- 资助金额:
$ 24.48万 - 项目类别:
UBIQUITIN AND CELLULAR FACTORS IN CORONAVIRUS ASSEMBLY
冠状病毒组装中的泛素和细胞因子
- 批准号:
7846495 - 财政年份:2009
- 资助金额:
$ 24.48万 - 项目类别:
UBIQUITIN AND CELLULAR FACTORS IN CORONAVIRUS ASSEMBLY
冠状病毒组装中的泛素和细胞因子
- 批准号:
7860419 - 财政年份:2009
- 资助金额:
$ 24.48万 - 项目类别:
Biological Effects of SARS-CoV Spike Polymorphisms
SARS-CoV 刺突多态性的生物学效应
- 批准号:
6825526 - 财政年份:2004
- 资助金额:
$ 24.48万 - 项目类别:
Adaptive MERS coronavirus-cell entry pathways and their relevance to virulence and antiviral strategies
适应性 MERS 冠状病毒细胞进入途径及其与毒力和抗病毒策略的相关性
- 批准号:
10229391 - 财政年份:2004
- 资助金额:
$ 24.48万 - 项目类别:
Adaptive MERS coronavirus-cell entry pathways and their relevance to virulence and antiviral strategies
适应性 MERS 冠状病毒细胞进入途径及其与毒力和抗病毒策略的相关性
- 批准号:
9209899 - 财政年份:2004
- 资助金额:
$ 24.48万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 24.48万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 24.48万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 24.48万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 24.48万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 24.48万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 24.48万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 24.48万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 24.48万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 24.48万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 24.48万 - 项目类别:
Continuing Grant